Physician profile
Eli Coria
NPI 1831658996
$3,838.10
in general payments reported to CMS, 2019-2025
22 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $913 · 2024: $1,350 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.24 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $556.99 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $453.39 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $442.18 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $276.24 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.15 | 2022-2025 | Jardiance, Synjardy, Trijardy Xr |
| Pfizer INC. | $218.81 | 2023-2025 | |
| Exact Sciences Corporation | $124.99 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $116.58 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $107.62 | 2023-2025 | Contrave, Onzetra Xsail |
| Supernus Pharmaceuticals, INC. | $104.02 | 2024 | Qelbree |
| Amgen INC. | $93.36 | 2024-2025 | Repatha, Otezla, Repatha |
| Azurity Pharmaceuticals, INC. | $82.15 | 2024-2025 | Horizant, Azmiro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.61 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $39.81 | 2023 | Rexulti, Abilify Maintena |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.02 | 2023-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.34 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2025 | |
| Integra Lifesciences Corporation | $21.13 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Sanofi Pasteur INC. | $16.90 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.90 | 2023 | Quviviq |
| Abbott Laboratories | $7.29 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Coria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.